Celltrion
068270.KS
#786
Rank
NZ$43.72 B
Marketcap
$211.67
Share price
-0.12%
Change (1 day)
-3.82%
Change (1 year)
Celltrion is a Korean pharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion.

Revenue for Celltrion (068270.KS)

Revenue in 2024 (TTM): NZ$3.25 Billion

According to Celltrion 's latest financial reports the company's current revenue (TTM ) is NZ$3.38 Billion. In 2023 the company made a revenue of NZ$2.60 Billion a decrease over the revenue in the year 2022 that were of NZ$2.76 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Celltrion from 2008 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) NZ$3.25 B24.78%
2023 NZ$2.60 B-5.53%
2022 NZ$2.76 B14.57%
2021 NZ$2.41 B9.29%
2020 NZ$2.20 B53.18%
2019 NZ$1.44 B8.18%
2018 NZ$1.33 B11.13%
2017 NZ$1.19 B42.65%
2016 NZ$0.83 B9.76%
2015 NZ$0.76 B33.41%
2014 NZ$0.57 B127.7%
2013 NZ$0.25 B-35.48%
2012 NZ$0.39 B
2010 NZ$0.20 B26.72%
2009 NZ$0.16 B29.33%
2008 NZ$0.12 B